tiprankstipranks
Senzime AB (SNZZF)
OTHER OTC:SNZZF

Senzime AB (SNZZF) Stock Price & Analysis

1 Followers

SNZZF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.25 - $1.00
Previous Close$0.59
Volume100.00K
Average Volume (3M)12.83K
Market Cap
$60.17M
Enterprise Value$56.07M
Total Cash (Recent Filing)kr58.39M
Total Debt (Recent Filing)kr14.67M
Price to Earnings (P/E)
Beta0.34
Aug 26, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding100,566,660
10 Day Avg. Volume0
30 Day Avg. Volume12,826
Standard Deviation0.30
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

SNZZF FAQ

What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was $0.25 and its highest was $1.00 in the past 12 months.
    What is Senzime AB’s market cap?
    Currently, no data Available
    When is Senzime AB’s upcoming earnings report date?
    Senzime AB’s upcoming earnings report date is Aug 26, 2024 which is in 92 days.
      How were Senzime AB’s earnings last quarter?
      Senzime AB released its earnings results on May 07, 2024. The company reported -$0.019 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.009.
        Is Senzime AB overvalued?
        According to Wall Street analysts Senzime AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Senzime AB pay dividends?
          Senzime AB does not currently pay dividends.
          What is Senzime AB’s EPS estimate?
          Senzime AB’s EPS estimate is -$0.02.
            How many shares outstanding does Senzime AB have?
            Senzime AB has 100,566,660 shares outstanding.
              What happened to Senzime AB’s price movement after its last earnings report?
              Senzime AB reported an EPS of -$0.019 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 3.077%.
                Which hedge fund is a major shareholder of Senzime AB?
                Currently, no hedge funds are holding shares in SNZZF
                ---

                Senzime AB Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                -41.00%
                12-Months-Change

                Fundamentals

                Return on Equity
                -39.14%
                Trailing 12-Months
                Asset Growth
                8.33%
                Trailing 12-Months

                Company Description

                Senzime AB

                Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.
                ---

                SNZZF Company Deck

                ---

                SNZZF Earnings Call

                Q1 2024
                0:00 / 0:00
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Anika Therapeutics
                Baxter International
                Becton Dickinson
                BioSig Technologies
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis